Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3-Reference-Cited by-同舟云学术

Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3

Published:2018-10-17 Issue:463 Volume:10 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Slaga Dionysos¹^ORCID,Ellerman Diego¹^ORCID,Lombana T. Noelle¹^ORCID,Vij Rajesh¹^ORCID,Li Ji¹^ORCID,Hristopoulos Maria¹,Clark Robyn¹^ORCID,Johnston Jennifer¹^ORCID,Shelton Amy¹,Mai Elaine¹,Gadkar Kapil¹,Lo Amy A.¹^ORCID,Koerber James T.¹^ORCID,Totpal Klara¹,Prell Rodney¹,Lee Genee¹,Spiess Christoph¹^ORCID,Junttila Teemu T.¹^ORCID

Affiliation:

1. Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

Abstract

T cell–dependent bispecific antibodies with bivalent low affinity binding to HER2 are more selective for tumor cells that overexpress the target.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference53 articles.

1. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

2. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

3. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia